Fused bicyclic-substituted amines as histamine-3 receptor...

Details Fused bicyclic-substituted amines as histamine-3 receptor... Fused bicyclic-substituted amines as histamine-3 receptor...

2008-01-29

2010-10-05

Chu, Yong (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S387000, C514S422000, C546S268100, C546S273400, C548S304100, C548S306100, C548S518000

Reexamination Certificate

active

07807697

ABSTRACT:
Compounds of formula (I)are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands and methods for using such compounds and compositions.

REFERENCES:
patent: 5612360 (1997-03-01), Boyd et al.
patent: 6420391 (2002-07-01), Konishi et al.
patent: 7094790 (2006-08-01), Cowart et al.
patent: 7358263 (2008-04-01), Cowart et al.
patent: 0754455 (1997-01-01), None
patent: 0978512 (2000-02-01), None
patent: 2010142 (1989-02-01), None
patent: 1178400 (1970-01-01), None
patent: 2001/39957 (2001-02-01), None
patent: 93/08179 (1993-04-01), None
patent: 94/08962 (1994-04-01), None
patent: 94/21626 (1994-09-01), None
patent: 94/24105 (1994-10-01), None
patent: 97/18201 (1997-05-01), None
patent: 97/31635 (1997-09-01), None
patent: 98/38156 (1998-09-01), None
patent: 98/57931 (1998-12-01), None
patent: 99/43672 (1999-09-01), None
patent: 00/06254 (2000-02-01), None
patent: 02/074758 (2002-09-01), None
patent: 2004/043458 (2004-05-01), None
Abreo et al., J. Med. Chem. 39: 817-825 (1996).
Andres et al., Eur. J. Org. Chem. 9:1719-1726 (2000).
Arrang et al., Nature 302:832-837 (1983).
Arrang et al., Nature 327:117-123 (1988).
Arrang et al., Eur. J. Pharm. 188: 219-227 (1990).
Bjenning et al., Abstracts, International Sendai Histamine Symposium, Sendai, Japan, #P39 (2000).
Cheng et al., Biochemical Pharmacology 22: 3099-3108 (1973).
De Almeida et al., Arch. Int. Pharmacodyn. 283:193-198 (1986).
Delaunois et al., Eur. J. Pharm. 277(2-3): 243-250 (1995).
Dimitriadou et al., Clinical Science 87(2): 151-163 (1994).
Dumery et al., Exp. Brain Res. 67:61-69 (1987).
Elworthy et al., Tetrahedron 50(20): 6089-6096 (1994).
Fitzsimons et al., Inflammation Res. 47 (Suppl 1): S50-S51 (1998).
Fox et al., Behav. Brain Res. 131:151-161 (2002).
Furniss et al., Vogel's Textbook of Practical Organic Chemistry, 5thedition, Longman Scientific & Technical, Essex CM20 2 JE, England, Table of Contents (1989).
Gaffield et al., Tetrahedron 37: 1861-1869 (1981).
Haas et al., Behav. Brain Res. 66:41-44 (1995).
Hatta et al., J. Pharm. Exp. Ther. 283:494-500 (1997).
Higuchi et al., Prodrugs as Novel Delivery Systems, vol. 14 of the A.C.S. Symposium Series (Table of Contents).
Imamura et al., Circ. Res. 78:475-481 (1996).
Imamura et al., Circ. Res. 78:863-869 (1996).
Itoh et al., Biol. Psych., 45(4): 475-481 (1999).
IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. 45:13-30 (1976).
Kamei et al., Jpn. J. Pharmacology. 57:437-482 (1991).
Kamei et al., Psychopharmacology 102:312-318 (1990).
Karrer et al., Helv. Chim. Acta 34:2202-2210 (1951).
Kim et al., Bioorg. Med. Chem. Lett. 6(1): 71-76 (1996).
Leurs et al., Progress Drug Res. 39:127-165 (1992).
Leurs et al., Progress in Drug Research 45:107-165 (1995).
Leurs et al., Trends in Pharm. Sci. 19:177-183 (1998).
Leurs et al., J. Pharm. and Exper. Ther.276: 1009-1015 (1996).
Levi et al., J. Pharm. Exp. Ther. 292:825-830 (2000).
Lin et al., Brain Res. 523:325-330 (1990).
Matsubara et al., Eur. J. Pharm. 224:145-150 (1992).
Mazurkiewic-Kwilecki et al., Can. J. Physiol. Pharmacology. 67:75-78 (1989).
McLeod et al., Progress in Resp. Research 31:133 (2001).
Monti et al., Neuropsychopharmacology 15:31-35 (1996).
Monti et al., Eur. J. Pharmacology. 205:283 (1991).
Murukami et al., Meth. Find. Exp. Clin. Pharmacology. 17 (C): 70-73 (1995).
Nijhuis et al., J. Org. Chem. 54(1): 209-216, 214 (1998).
Nugiel et al., Journal of Medicinal Chemistry 40:1465-1474 (1997).
Onodera et al., Prog. Neurobiol. 42:685 (1994).
Pan et al., Methods and Findings in Experimental and Chemical Phar. 20:771-777 (1998).
Panula et al., Neuroscience 44:465-481 (1998).
Panula et al., Neuroscience 82:993-997 (1997).
Perez-Garcia et al., Psychopharmacology (Berl) 142(2): 215-220 (1999).
Phillips et al., Annual Reports in Medicinal Chemistry 33:31-40 (1998).
Polish Med. Sci. Mon. 4(5): 747 (1998).
Poste et al., Prescott, Ed., Methods in Cell Biology, vol. XIV, Academic Press, New York, N.Y., p. 33-71 et seq. (1976).
Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987).
Rouleau et al., J. Pharmacol. Exp. Ther. 281:1085 (1997).
Sakai et al., Life Sci. 48:2397-2404 (1991).
Schwartz et al., Psychopharmacology, The Fourth Generation of Progress and Kupfer (eds). Raven Press New York, 397-405 (1995).
Schwartz, Physiol. Review 71:1-51 (1991).
Shaywitz et al., Psychopharmacology 82:73-77 (1984).
Szelag, Med. Sci. Monit. 4(5): 747-755 (1998).
Tedford et al., J. Pharmacol. Exp. Ther. 275:598-604 (1995).
Tedford et al., Soc. Neurosci. Abstr. 22:22 (1996).
Tedford, Pharm. Library vol. 30: 269-286 (1998).
Wada et al., Trends in Neuroscience 14:415 (1991).
Yates et al., Abstract, Society for Neuroscience 102.10:219 (2000).
Yokoyama et al., CNS Drugs 5(5): 321-330 (1995).
Yokoyama et al., Eur. J. Pharmacology 234:129 (1993).

Affiliated with

Also associated with

Rating

Fused bicyclic-substituted amines as histamine-3 receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fused bicyclic-substituted amines as histamine-3 receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused bicyclic-substituted amines as histamine-3 receptor... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4242368